BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Biotech Bay

  $100M Richer, Neuron23 Introduces LRRK2 inhibitor for Parkinson’s

  Neuron23 announced today that it closed a $100 million Series C financing round led by SoftBank Vision Fund 2.

  March 30, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Study Suggests Far-UV Light Could Save Us from the Next Pandemic

  Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.

  March 30, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Identifying Missing Links - and Why Certain Drugs Don’t Work - in Alzhiemer’s

  A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.

  March 30, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  FDA

  Honing in On Neurometabolic Diseases, Orchard Slashes 30% of Workforce

  Orchard Therapeutics announced today that it intends to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs.

  March 30, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Money on the Move: March 23-29

  This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding.

  March 30, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Safety Concerns Doom Akebia’s Chronic Kidney Disease Drug

  The FDA has rejected Cambridge, Mass.-based Akebia Therapeutics’ New D2rug Application (NDA) for vadadustat, a therapeutic for anemia due to chronic kidney disease (CKD).

  March 30, 2022

   · 

  2 min read

   · 

  Rosemary Scott
• 

  Business

  BioNTech Set to Join Ranks of Largest Drugmakers in the World

  After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.

  March 30, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  BioMidwest

  Study: Preclinical Mouse Model Shows Cognitive Improvement in Down Syndrome

  Partner Therapeutics, based in Lexington, Mass., has teamed up with the University of Colorado to study mouse models of Down syndrome and compounds that might improve memory with age.

  March 30, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Employer Resources

  How to Manage Gen Z Employees in the Biopharma Industry

  Successfully managing Gen Z employees in the workplace requires knowing about their distinctive traits and the factors that set them apart.

  March 30, 2022

   · 

  5 min read

   · 

  Brandi Marcene
• 

  Drug Development

  Biogen Submits Final Plan for Confirmatory Aduhelm Trial

  Biogen will await word after submitting the final study protocol for its confirmatory Phase IV ENVISION trial of Aduhelm to the U.S. Food and Drug Administration (FDA).

  March 30, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS